Other investigational agent(s) within 21 days prior starting to study treatment.
Use of any investigational agent within 28 days prior to randomization.
Received another investigational agent within 30 days of enrollment
Prior participant in another protocol using an investigational agent within 5 half-lives of the investigational agent
Received an investigational agent within 30 days prior to enrollment
Received an investigational agent for any indication within 30 days prior to first treatment.
Use of investigational agent within 28 days prior to randomization
Participants is taking another investigational agent
Received an investigational agent within 30 days prior to starting study treatment
The patient has received treatment with an investigational systemic anticancer agent within 28 days prior to C1D1.
Biologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is required
Have taken an investigational agent within 30 days of visit 1
Use of any standard chemotherapy or other investigational agent(s) within 1 week of study enrollment
Received an investigational agent within 30 days prior to enrollment
Patients receiving investigational agent within 30 days of enrollment. However, the principal investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of alpha-1-antitrypsin.
Received an investigational agent within 30 days prior to enrollment
Received an investigational agent within 30 days prior to enrollment
Patient is currently using, or planning to use another investigational agent
Use of an investigational agent within 4 weeks of enrollment (day 1)
Use of other investigational agent for prostate cancer
Received an investigational agent within 30 days prior to enrollment
Patients who participated in any therapeutic clinical study with an investigational agent within the last 30 days
Cytotoxic therapy or investigational agent use within 28 days
Treatment with a prior investigational agent within 30 days of first dose of investigational medication
Exposure to any therapeutic agent (investigational or conventional) within 7 days of date of randomization or to any agent for which 5 half lives have not elapsed
Receipt of any investigational agent or study treatment within 30 days prior to C1D1
Treatment with other investigational agent(s) within 30 days of planned lymphodepletion
Concurrent use of investigational therapeutic agent
Investigational agent within 30 days of enrollment without approval from the sponsor- principal investigator (PI)
Concurrent use of investigational therapeutic agent
At least 7 days after the last dose of a biologic agent.
Exposure to any investigational agent within 30 days of date of randomization.
The use of any investigational agent in the month before enrollment into the study
Received an investigational agent within 30 days prior to enrollment
Received an investigational agent within 30 days prior to enrollment
Received any investigational agent for any indication within 30 days prior to first treatment.
Investigational agent: >= 28 days must have elapsed from treatment with a different investigational agent
Patients who have received any investigational treatment agent within the last 28 days.
Received an investigational agent within 30 days prior to enrollment
Patients who have received another investigational agent within the previous 3 months
Use of any investigational agent within 30 days of the first radiation dose
Use of investigational agent within last 14 days
Received any investigational agent within the 14 days before the start of ALT-803
Use of an investigational agent within 4 weeks of enrollment
Treatment with any other investigational agent within 28 days prior to enrolment.
Use of any investigational agent within the last 28 days. For classes of investigational agents that are not known to have prolonged toxicities the wash-out time may be decreased to 14 days after agreement with the Medical Monitor.
Subjects who have received an investigational agent within 30 days OR within 5 half-lives of the investigational agent (whichever is shorter) prior to the possible enrollment date on this study
Patient who has received investigation agent within 30 days prior to enrollment
Received an investigational agent within 30 days prior to enrollment
Patients who have received any investigational agent within 30 days prior to day 1
Subjects who received any investigational agent ?28 days of study drug initiation.
Subjects who received an investigational agent <14 days prior to their first day of study drug administration.
The patient has received treatment with another investigational agent within 14 days of study entry.
? 28 days elapsed from the administration of any investigational agent
Use of any investigational agent within the 4 weeks preceding enrollment
Received an investigational agent within 4 weeks prior to enrollment
Previously received an investigational antineoplastic agent for NSCLC.
Use of any investigational agent within 28 days of randomization.
Any investigational agent within the previous 30 days.
Patients who have received any investigational agent, chemotherapy, interferon-alfa, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to day 1
Exposure to any investigational agent, systemic chemotherapy, or therapeutic radiation within 21 days of enrollment (Part 1) or randomization (Part 2).
Previously received treatment with RGX-104 or another investigational agent that is a known LXR agonist.
Use of an investigational agent or an investigational device within 28 days before administration of first dose of NKTR-214.
Concurrent use of investigational therapeutic agent
Patients must have received their last dose of any other investigational agent greater than 28 days prior to enrollment (with exception of fluorothymidine F-18 [FLT])\r\n* Patients must have received their last dose of any other biologic agent greater than 7 days prior to enrollment
Use of investigational agent within 28 days prior to Randomization
Subjects who received an investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-120 should not occur before a period ?5 half-lives of the investigational agent has elapsed.
Use of an investigational agent within 2 weeks of enrollment (day 1 visit)
Received an investigational agent within 4 weeks prior to enrollment
Subjects who are receiving any other investigational agents or who have received an investigational agent within 28 days prior to enrollment (does not apply to participation in survival follow up), or who have previous exposure to vandetanib
Subjects who received a small molecule investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-221 should not occur before a period ?5 half-lives of the investigational agent has elapsed.
Patients who have received any investigational agent within 4 weeks of enrollment
Receipt of any other investigational agent within the 28 days prior to Day 1.
Treatment with an investigational agent ? 30 days prior to randomization
Concurrent therapy with any other investigational agent
Patients who have received any other investigational agent in a 28-day period prior to enrollment in this study
Received an investigational agent within 30 days prior to enrollment
Received anticancer agent(s) or an investigational agent within 21 days prior to C1D1, or radiotherapy within 28 days prior Cycle 1 Day 1
Use of an investigational agent, including an investigational anti-cancer agent, within 14 days prior to the first dose of study drug
Treatment with investigational agent within 30 days prior to enrollment
Treatment with a an investigational agent within 30 days prior to the first dose of dasatinib/ATRA or planning to receive an investigational agent during the study
Patients who have received any investigational agent, chemotherapy, interferon-?, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to first dose
An investigational agent within the past 30 days
Current use of an investigational agent
Participation in an investigational research study using an investigational agent within 30 days of screening
Use of an investigational therapeutic agent with 4 weeks of enrollment
Treatment with an investigational agent within 30 days prior to the first dose of SNX?5422 or planning to receive an investigational agent during the study.
Use of any investigational agent within 28 days prior to Baseline.
Received an investigational agent within 30 days prior to enrollment
Received an investigational agent for another disease within 30 days prior to enrollment
Subjects who have received any other investigational drug or agent within 28 days of first dose of TH-302
Use of any other investigational agent within 21 days before day 1.
Use of any investigational agent within the last 28 days
Received an investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-221 should not occur before a period ?5 half-lives of the investigational agent has elapsed
Exposure to any investigational agent within 30 days of date of randomization.
Exposure to any investigational agent within 30 days of Randomization.
Recently received an investigational agent or device
Received an investigational agent within 30 days prior to enrollment
Use of an investigational therapeutic agent within 30 days
Concurrent use of other investigational agent
Subject may not receive another investigational agent.
The patient received treatment with another investigational agent within 14 days of screening.
Must be 28 days from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:
Use of an investigational agent within the past 30 days
Use of any investigational agent within 28 days prior to start of CA-4948
Treatment with any other investigational agent within 28 days prior to randomization
Any other investigational agent within 28 days of study entry
Patient received chemotherapy, biological or investigational agent ? 28 days prior to enrollment.
Received an investigational agent for any indication within 30 days prior to first treatment
Received an investigational agent within 30 days prior to enrollment
Concurrent use of investigational therapeutic agent
Concurrent use of investigational therapeutic agent
Received an investigational agent within 30 days prior to enrollment
28 days from the administration of any investigational agent
Patient is currently receiving or has received another investigational agent within 30 days or monoamine oxidase inhibitor within 14 days prior to Lazanda administration
Received an investigational agent within 30 days prior to enrollment
Concurrent therapy with an investigational agent
Received any investigational agent =< 28 days before Treg infusions
Use of any investigational agent within 30 days of randomization
Use of investigational agent within 30 days of study entry
Has received an investigational study agent within the previous 30 days, or is currently participating in or scheduled to participate in any other clinical study with an investigational agent during the 12-week study period
Exposure to any investigational agent (defined as any agent not approved by the Food and Drug Administration [FDA]) within 30 days prior to the Screening Visit
Use of non-study investigational agent(s) =< 3 months prior to randomization
Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to surgery
Subjects must not receive concurrent or prior use of an immunosuppressive agent within 14 days of the first dose of investigational agent, with the following exceptions and notes:
Subjects must not have received another investigational agent within the shorter of 4 weeks or 5 half-lives before the first dose of investigational agent.
Received an investigational agent within 30 days prior to enrollment
Use of an investigational agent within 4 weeks of enrollment
Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to surgery